Yichang Tianrui Biopharm Co., Ltd

Yichang Tianrui Biopharm Co., Ltd, a wholly-owned subsidiary of Humanwell Group (Yichang Humanwell Pharmaceutical), specializes in the R&D, production, and sales of specialty active pharmaceutical ingredients (APIs). Leveraging Humanwell’s global leadership in anesthesia and analgesia, the company has established a modern manufacturing system compliant with international cGMP standards, equipped with advanced technical platforms including high-pressure hydrogenation, lyophilization, and spray drying. Its core business covers specialty APIs (such as Osimertinib Mesylate，Samidorphan L-Malate, Maribavir, Letermovir, Lumateperone Tosylate and Baricitinib), pharmaceutical intermediates (including 2-(2-Amino-5-bromobenzoyl) pyridine and 7-ANCA), as well as veterinary APIs (such as Tiletamine Hydrochloride, Atipamezole Hydrochloride, and Alfaxalone). Additionally, the company offers customized development and manufacturing services (CDMO/CMO) for high potency APIs (HPAPIs) and products requiring specialized processes, catering to diverse client needs.
Established on November 15, 2022, Yichang Tianrui is located in the Baiyang Bio-industrial Park, Yichang High-Tech Development Zone, Hubei Province. To strengthen the foundation for specialty API manufacturing, the company has invested a total of $277 million, covering an area of 220,000 square meters, with a planned layout of 13 international-standard GMP workshops. The project is being implemented in 3 phases. To date, Phase I has been successfully completed with a total investment of $112 million, including 2 GMP-compliant commercial production workshops and 9 dedicated production lines, providing a solid infrastructure for the consistent delivery of high-quality pharmaceutical ingredients.